Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 22.82 USD -1.13% Market Closed
Market Cap: 1.1B USD

Urogen Pharma Ltd
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Urogen Pharma Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Urogen Pharma Ltd
NASDAQ:URGN
Depreciation & Amortization
-$319k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Depreciation & Amortization
$15.2m
CAGR 3-Years
11%
CAGR 5-Years
26%
CAGR 10-Years
17%
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Depreciation & Amortization
$292k
CAGR 3-Years
-26%
CAGR 5-Years
2%
CAGR 10-Years
31%
Entera Bio Ltd
NASDAQ:ENTX
Depreciation & Amortization
$34k
CAGR 3-Years
-30%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Depreciation & Amortization
$381k
CAGR 3-Years
-22%
CAGR 5-Years
-23%
CAGR 10-Years
-16%
M
Matricelf Ltd
TASE:MTLF
Depreciation & Amortization
₪988k
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Urogen Pharma Ltd
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

URGN Intrinsic Value
29.67 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Urogen Pharma Ltd's Depreciation & Amortization?
Depreciation & Amortization
-319k USD

Based on the financial report for Sep 30, 2025, Urogen Pharma Ltd's Depreciation & Amortization amounts to -319k USD.

Back to Top